摘要
实体器官移植(SOT)受者是新型冠状病毒肺炎(COVID⁃19)的高风险人群,该人群接种COVID⁃19疫苗的安全性和有效性倍受关注。目前有关SOT受者接种COVID⁃19疫苗的研究报道主要集中在接种信使核糖核酸疫苗,也有少数接种重组腺病毒载体疫苗的个案报道。这些研究结果显示,SOT受者接种COVID⁃19疫苗是安全的,但免疫应答率较低,接种疫苗后的突破性感染发生率高于一般人群。根据目前的研究结果,SOT受者可以在器官移植后1~3个月开始接种COVID⁃19疫苗,接种疫苗后仍需要注意预防COVID⁃19,避免发生疫苗突破性感染。
Solid organ transplant(SOT)recipients are a high⁃risk population for coronavirus disease 2019(COVID⁃19),and the safety and efficacy of COVID⁃19 vaccines in this population is of great concern.At present,the published studies on COVID⁃19 vaccines for SOT recipients are mainly about mRNA vaccines and there are a few cases reports on recombinant adenovirus vector⁃based vaccines.These results show that the COVID⁃19 vaccines are safe for the SOT recipients,but the immune response rates are lower and the incidence of vaccine breakthrough infections is higher than that in the general population.Based on the results of the current studies,SOT recipients can start to be vaccinated with COVID⁃19 vaccines 1 to 3 months after organ transplantation.Prevention of COVID⁃19 after vaccination is still neces⁃sary to avoid vaccine breakthrough infections.
作者
王玥媛
周杨林
阳柳
苟梦秋
边原
Wang Yueyuan;Zhou Yanglin;Yang Liu;Gou Mengqiu;Bian Yuan(Department of Pharmacy,Sichuan Academy of Medical Sciences&Sichuan Provincial People′s Hospital,Affiliated Hospital of University of Electronic Science and Technology,Personalized Drug Therapy Key Laboratory of Sichuan Province,Chengdu 610072,China)
出处
《药物不良反应杂志》
CSCD
2021年第7期348-351,共4页
Adverse Drug Reactions Journal
基金
国家临床重点专科建设项目(30305030698)。
